---
title: "Tsumura Aligns Yomeishu Share Acquisition With Long-Term Kampo Healthcare Vision"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276774566.md"
description: "Tsumura & Co. has signed a contract to acquire shares of Yomeishu Seizo Co., Ltd., aligning with its long-term strategy, TSUMURA VISION “Cho-WA” 2031. This acquisition aims to enhance Tsumura's position in Kampo and traditional Chinese medicine, focusing on preventive healthcare and personalized well-being. The latest analyst rating for Tsumura's stock (JP:4540) is a Buy, with a price target of Yen4762.00. Tsumura operates in the pharmaceutical sector, emphasizing evidence-based treatments and a supportive corporate culture."
datetime: "2026-02-24T18:23:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276774566.md)
  - [en](https://longbridge.com/en/news/276774566.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276774566.md)
---

# Tsumura Aligns Yomeishu Share Acquisition With Long-Term Kampo Healthcare Vision

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest update is out from Tsumura & Co ( (JP:4540) ).

Tsumura & Co. has concluded a contract to acquire shares of Yomeishu Seizo Co., Ltd., aligning the deal with its long-term TSUMURA VISION “Cho-WA” 2031 strategy. The vision emphasizes contributing to a healthier society by developing evidence-based diagnostic methods for pre-symptomatic diseases and delivering Kampo and traditional Chinese medicine solutions tailored to personal health conditions.

The acquisition supports Tsumura’s ambition to expand its footprint in traditional medicine while reinforcing a corporate culture that values dialogue and employee potential. By integrating Yomeishu Seizo into its broader strategy, Tsumura aims to strengthen its unique positioning in Kampo and traditional Chinese medicine, enhancing its role in preventive healthcare and personalized well-being services.

The most recent analyst rating on (JP:4540) stock is a Buy with a Yen4762.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.

**More about Tsumura & Co**

Tsumura & Co. operates in the pharmaceutical and healthcare sector, focusing on Kampo and traditional Chinese medicine. The company aims to provide evidence-based treatments and services tailored to individual life stages, symptoms, genetic profiles, and living environments, with an emphasis on building a healthy society and a supportive, dialogue-driven corporate culture.

**Average Trading Volume:** 309,649

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** Yen311.7B

Learn more about 4540 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [2540.JP](https://longbridge.com/en/quote/2540.JP.md)
- [4540.JP](https://longbridge.com/en/quote/4540.JP.md)

## Related News & Research

- [Investors pull more from private credit funds for the wealthy than they commit in Q1, RA Stanger says](https://longbridge.com/en/news/286436770.md)
- [Shinnihonseiyaku Lifts Earnings, Keeps Forecast and Plans Higher Dividend](https://longbridge.com/en/news/286216811.md)
- [Sofis Partners with Arcadea Group](https://longbridge.com/en/news/286380775.md)
- [Vital Healthcare Property Trust Secures Longer-Term, Cheaper Debt to Bolster Capital Flexibility](https://longbridge.com/en/news/286200256.md)
- [Tecomet and Orchid Complete Transaction, Creating a Scaled Global Manufacturing Platform](https://longbridge.com/en/news/286444110.md)